×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BCDA – biocardia, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BCDA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/16
08:36 am
bcda
BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023) [Yahoo! Finance]
Medium
Report
BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023) [Yahoo! Finance]
11/14
01:34 pm
bcda
BioCardia, Inc. (NASDAQ: BCDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Medium
Report
BioCardia, Inc. (NASDAQ: BCDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
11/14
02:31 am
bcda
BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ... [Yahoo! Finance]
High
Report
BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ... [Yahoo! Finance]
11/13
04:22 pm
bcda
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results [Yahoo! Finance]
High
Report
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results [Yahoo! Finance]
11/13
04:05 pm
bcda
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results
High
Report
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results
11/6
07:00 am
bcda
BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024
Low
Report
BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024
10/28
11:18 am
bcda
BioCardia, Inc. (NASDAQ: BCDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Low
Report
BioCardia, Inc. (NASDAQ: BCDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
10/28
09:00 am
bcda
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
Low
Report
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
11/19
08:00 am
bcda
Form 4 BioCardia, Inc. For: Nov 15 Filed by: Altman Peter
Low
Report
Form 4 BioCardia, Inc. For: Nov 15 Filed by: Altman Peter
11/13
04:10 pm
bcda
Form 8-K BioCardia, Inc. For: Nov 13
High
Report
Form 8-K BioCardia, Inc. For: Nov 13
11/13
04:07 pm
bcda
Form 10-Q BioCardia, Inc. For: Sep 30
High
Report
Form 10-Q BioCardia, Inc. For: Sep 30
10/28
09:00 am
bcda
Form 8-K BioCardia, Inc. For: Oct 28
High
Report
Form 8-K BioCardia, Inc. For: Oct 28
10/16
09:58 pm
bcda
Form 4 BioCardia, Inc. For: Oct 11 Filed by: GILLIS EDWARD M
Medium
Report
Form 4 BioCardia, Inc. For: Oct 11 Filed by: GILLIS EDWARD M
10/16
09:57 pm
bcda
Form 4 BioCardia, Inc. For: Oct 11 Filed by: Altman Peter
Medium
Report
Form 4 BioCardia, Inc. For: Oct 11 Filed by: Altman Peter
10/16
09:57 pm
bcda
Form 4 BioCardia, Inc. For: Oct 11 Filed by: McClung David
Medium
Report
Form 4 BioCardia, Inc. For: Oct 11 Filed by: McClung David
10/16
09:57 pm
bcda
Form 4 BioCardia, Inc. For: Oct 11 Filed by: Blank Andrew Scott
Medium
Report
Form 4 BioCardia, Inc. For: Oct 11 Filed by: Blank Andrew Scott
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/28
BioCardia Awarded New U.S. Patent Covering Helix System for Local Biotherapeutic Delivery of Autologous and Allogenic Cells to the Heart
52.7%
10/1 BioCardia Initiates Commercial Release of AVANCE Steerable Introducer Designed to Enhance Physician Control for Complex Cardiac Procedures 15.2%
7/25 BioCardia Signs Exclusive Development Agreement With AstraZeneca 14.8%
1/8 BioCardia Announces New U.S. Patent Covering CardiAMP Cell Therapy and Issuance of Two Asian Patents Covering Radial Artery Approach for Cardiac Cell and Gene Therapy Delivery 13.9%
7/30 Form CERT BioCardia, Inc. 13.7%
4/1 BioCardia Inc (OTCMKTS: BCDA) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $9.00 price target on the stock. 9.9%
5/20 BioCardia Reports 2019 First Quarter Financial Results and Business Highlights 6.5%
3/12 BIOCARDIA ANNOUNCES TIMING FOR PRESPECIFIED DATA SAFETY MONITORING BOARD REPORT ON PIVOTAL CARDIAMP HEART FAILURE TRIAL 5.6%
10/8 BioCardia Receives CE Mark Renewal For Helix Biotherapeutic Delivery Catheter And Morph Guide Catheter Through May 2024 4.4%
2/17 BioCardia Inc (OTCMKTS: BCDA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 4.2%
10/1 BioCardia Initiates Commercial Release of AVANCE Steerable Introducer Designed to Enhance Physician Control for Complex Cardiac Procedures 15.2%
7/25 BioCardia Signs Exclusive Development Agreement With AstraZeneca 14.8%
1/8 BioCardia Announces New U.S. Patent Covering CardiAMP Cell Therapy and Issuance of Two Asian Patents Covering Radial Artery Approach for Cardiac Cell and Gene Therapy Delivery 13.9%
7/30 Form CERT BioCardia, Inc. 13.7%
4/1 BioCardia Inc (OTCMKTS: BCDA) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $9.00 price target on the stock. 9.9%
5/20 BioCardia Reports 2019 First Quarter Financial Results and Business Highlights 6.5%
3/12 BIOCARDIA ANNOUNCES TIMING FOR PRESPECIFIED DATA SAFETY MONITORING BOARD REPORT ON PIVOTAL CARDIAMP HEART FAILURE TRIAL 5.6%
10/8 BioCardia Receives CE Mark Renewal For Helix Biotherapeutic Delivery Catheter And Morph Guide Catheter Through May 2024 4.4%
2/17 BioCardia Inc (OTCMKTS: BCDA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 4.2%
TOP News Decliners
8/2
BioCardia Announces Pricing of $10.0 Million Public Offering and Uplisting to Nasdaq
-64.3%
8/1 BioCardia Inc (OTCMKTS: BCDA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -17.6%
7/23 Form S-1/A BioCardia, Inc. -14.6%
10/2 BioCardia Announces the Appointment of Two New Board Members -11.3%
9/20 BioCardia Inc (OTCMKTS: BCDA) is now covered by analysts at Dawson James. They set a "buy" rating and a $24.00 price target on the stock. -7.7%
9/19 Biocardia Inc (NYSE: BCDA) had its "buy" rating re-affirmed by analysts at Dawson James. -6.0%
4/30 Biocardia Announces FDA-Recommended Modifications to Primary Endpoint for Cardiamp Cell Therapy Heart Failure Trial to Support Marketing Approval -5.0%
8/6 Form 4 BioCardia, Inc. For: Jul 05 Filed by: STERTZER SIMON H -4.9%
5/9 Form 8-K BioCardia, Inc. For: May 08 -4.3%
3/31 BIOCARDIA ANNOUNCES POSITIVE DSMB RECOMMENDATION TO CONTINUE PHASE III PIVOTAL CARDIAMP HEART FAILURE STUDY, AS PLANNED -3.1%
8/1 BioCardia Inc (OTCMKTS: BCDA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -17.6%
7/23 Form S-1/A BioCardia, Inc. -14.6%
10/2 BioCardia Announces the Appointment of Two New Board Members -11.3%
9/20 BioCardia Inc (OTCMKTS: BCDA) is now covered by analysts at Dawson James. They set a "buy" rating and a $24.00 price target on the stock. -7.7%
9/19 Biocardia Inc (NYSE: BCDA) had its "buy" rating re-affirmed by analysts at Dawson James. -6.0%
4/30 Biocardia Announces FDA-Recommended Modifications to Primary Endpoint for Cardiamp Cell Therapy Heart Failure Trial to Support Marketing Approval -5.0%
8/6 Form 4 BioCardia, Inc. For: Jul 05 Filed by: STERTZER SIMON H -4.9%
5/9 Form 8-K BioCardia, Inc. For: May 08 -4.3%
3/31 BIOCARDIA ANNOUNCES POSITIVE DSMB RECOMMENDATION TO CONTINUE PHASE III PIVOTAL CARDIAMP HEART FAILURE STUDY, AS PLANNED -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: